You searched for
Tag:
Care
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05/05/2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12/04/2023
2022 for Chiesi: The Group’s international growth continues
05/04/2023
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis
22/02/2023
Chiesi appoints Giuseppe Accogli as new Group CEO
27/01/2023
Chiesi Group endorses the Manifesto Against Gender-Based Violence
28/11/2022
Chiesi Group and Aptar partner to bring to market Disease Management Platform for Patients with Asthma and COPD
18/10/2022
Chiesi Group brings together experts to discuss care for respiratory patients and presents a new treatment option for COPD at ERS Congress
05/09/2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27/07/2022
Chiesi Group continues to grow
31/03/2022
A new clinical framework redefines the diagnosis of COPD Exacerbations
16/12/2021
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
14/12/2021
Chiesi Research Centre: 10 years’ scientific innovation serving the community
18/10/2021
New organisational order for the Chiesi Foundation
03/05/2021
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
22/03/2021